drugset / Trial / NCT01123538

Progestagen Type in Postmenopausal Hormone Therapy and Blood Gene Expression Profile

NCT01123538

Phase 4 Unknown 40 enrolled University Hospital of North Norway
RandomizedParallel-groupOpen-label

Summary

The purpose of this study is to compare combined postmenopausal hormone therapy natural progesterone to the one containing synthetic progestagen (i.e. chlormadinone acetate) at the blood transcriptome level.

Timeline

Start
2008-12
Primary completion
2011-10
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Progesterone Other / unclassified 200 mg Oral
Comparator chlormadinone acetate Small molecule 5 mg Oral
Background Estradiol Other / unclassified 0.05 mg Other

Indications

No indication recorded.